Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

VDT PACE-Like Therapy for Relapsed/Refractory MM

Am J Hematol; ePub 2017 Nov 10; Lakshman, et al

The combination chemotherapy regimen VDT PACE and its variations are effective in patients intensely pre-treated for relapsed/refractory multiple myeloma, according to an intent-to-treat analysis involving 141 individuals. Participants had relapsed/refractory multiple myeloma and were treated with VDT PACE-like regimens (VLPRs) at a single center between 2006 and 2017. They received a median of 4 prior treatments. ~Two-thirds had prior stem cell transplant (SCT). ~Half had high-risk cytogenetics. Among the results:

  • ~7 in every 10 patients achieved ≥minimal response.
  • 54% achieved ≥partial response.
  • 1 in every 10 achieved ≥very good partial response.
  • Median progression-free and overall survival were 3.1 and 8.1 months, respectively.
  • 8 in every 10 received therapy after VPLR; 63% received systemic chemotherapy and 39% SCT.
  • Those who received SCT survived a median of 5.1 months.
  • Patients ≥60 years of age and those with R-ISS III stage experienced shorter overall survival.

Citation:

Lakshman A, Singh P, Rajkumar S, et al. Efficacy of VDT PACE-like regimens in treatment of relapsed/refractory multiple myeloma. [Published online ahead of print November 10, 2017]. Am J Hematol. doi:10.1002/ajh.24954.

This Week's Must Reads

Oncologists file suit challenging Part B payment reductions, May 30 letter to HHS Secretary Alex Azar alerting him to the legal action, which was filed on May 31.

One-third of IDH1-mutated AML cases have complete response to ivosidenib , Pollyea DA, et al. J Clin Oncol 36, 2018 (suppl) annual meeting of the American Society of Clinical Oncology; abstr 7000.

Ruxolitinib add-on boosted myeloma response, Berenson JR, et al. J Clin Oncol 36, 2018, suppl. (ASCO 2018, annual meeting of the American Society of Clinical Oncology); abstr 8005.

Getting to MRD in ALL boosted survival, Hay KA. ASCO 2018 (annual meeting of the American Society of Clinical Oncology), Abstract 7005.

CLL gets to MRD with combo therapy, Wierda WG et al. ASCO 2018 (annual meeting of the American Society of Clinical Oncology), Abstract 7502.

Must Reads in Multiple Myeloma

Ruxolitinib add-on boosted myeloma response, Berenson JR, et al. J Clin Oncol 36, 2018, suppl. (ASCO 2018, annual meeting of the American Society of Clinical Oncology); abstr 8005.

Refractory myeloma may respond to ruxolitinib add-on, Berenson JR, et al. J Clin Oncol 36, 2018 (suppl; abstr 8005).

Add-on ibrutinib boosted response in relapsed multiple myeloma, Chari A et al. Leuk Lymphoma. 2018 Apr 4. doi: 10.1080/10428194.2018.1443337.

Myeloma more likely to go untreated in dual Medicare-Medicaid recipients, Fakhri B et al. Clin Lymphoma Myeloma Leuk. Mar 2018;18(3):219-24.

In myeloma, go for a third transplant, Garderet L et al. Biol Blood Marrow Transplant. 2018 Feb 3. doi: 10.1016/j.bbmt.2018.01.035